Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

SUMMIT, N.J.--(BUSINESS WIRE)--March 25, 2019 Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news